Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.

Although most founder mutation carriers of hypertrophic cardiomyopathy (HCM), such as the cardiac myosin-binding protein C gene (MYBPC3), arose from a common ancestor exhibit favorable clinical phenotypes, there still remain small fractions of these carriers associated with increased cardiovascular events. However, few data exist regarding the defining factors that modify phenotypes of these patients, particularly in terms of multiple gene mutations. Therefore, we assessed genotype-phenotype correlations and investigated factors that contribute to phenotypic diversities of mutation carriers from 488 unrelated HCM probands. A prevalent founder mutation (Val762Asp) in MYBPC3 was identified in 33 subjects from 19 families. Among them, 28 carriers harbored an isolated Val762Asp mutation and exhibited a late onset of overt HCM compared with other MYBPC3 mutation carriers (62.8 ± 3.0 vs 50.1 ± 2.6 yr, P < 0.05). In contrast, the remaining five carriers had additional sarcomere gene mutations (3 carriers in MYBPC3 and 2 carriers in the cardiac troponin T gene). Of these five carriers, two carriers showed early disease onset and one carrier exhibited end-stage HCM. These phenotypes were recapitulated in zebrafish models; injection of MYBPC3 Val762Asp alone did not alter ventricular size or function, but ventricular dimension was significantly increased when MYBPC3 Val762Asp mRNA was coinjected with MYBPC3 Arg820Gln mRNA. These results demonstrate that MYBPC3 Val762Asp may be associated with unfavorable HCM phenotypes in some cases when combined with another MYBPC3 mutation.

[1]  K. Hayashi,et al.  Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects , 2014, Heart and Vessels.

[2]  Lian‐Yu Lin,et al.  Inactivation of Myosin Binding Protein C Homolog in Zebrafish as a Model for Human Cardiac Hypertrophy and Diastolic Dysfunction , 2013, Journal of the American Heart Association.

[3]  Perry M Elliott,et al.  A systematic review and meta-analysis of genotype–phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations , 2013, Heart.

[4]  E. Argulian,et al.  Antihypertensive therapy in hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[5]  K. Hayashi,et al.  Impact of Systolic Dysfunction in Genotyped Hypertrophic Cardiomyopathy , 2013, Clinical cardiology.

[6]  M. Tristani-Firouzi,et al.  An In Vivo Cardiac Assay to Determine the Functional Consequences of Putative Long QT Syndrome Mutations , 2013, Circulation research.

[7]  M. Isobe,et al.  Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[8]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[9]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[10]  T. Arimura,et al.  Genetic screening and double mutation in Japanese patients with hypertrophic cardiomyopathy. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[11]  J. Seidman,et al.  Narrative Review: Harnessing Molecular Genetics for the Diagnosis and Management of Hypertrophic Cardiomyopathy , 2010, Annals of Internal Medicine.

[12]  W. Chung,et al.  Short Communication: The Cardiac Myosin Binding Protein C Arg502Trp Mutation: A Common Cause of Hypertrophic Cardiomyopathy , 2010, Circulation research.

[13]  Michael J Ackerman,et al.  Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.

[14]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[15]  H. Watkins,et al.  Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency* , 2009, Circulation research.

[16]  C. Tyler-Smith,et al.  A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia , 2009, Nature Genetics.

[17]  F. T. ten Cate,et al.  Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction , 2009, Circulation.

[18]  Masahiko Hibi,et al.  Genetic dissection of neural circuits by Tol2 transposon-mediated Gal4 gene and enhancer trapping in zebrafish , 2008, Proceedings of the National Academy of Sciences.

[19]  J. Seidman,et al.  Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics , 2007, Journal of cardiovascular electrophysiology.

[20]  K. Kawakami,et al.  A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. , 2007, The Journal of clinical investigation.

[21]  K. Hayashi,et al.  Differences in the diagnostic value of various criteria of negative T waves for hypertrophic cardiomyopathy based on a molecular genetic diagnosis. , 2007, Clinical science.

[22]  F. Girolami,et al.  A molecular screening strategy based on β-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy , 2006, Journal of cardiovascular medicine.

[23]  T. Kubo,et al.  Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese. , 2005, Journal of the American College of Cardiology.

[24]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[25]  N. Alpert,et al.  Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations. , 2005, American journal of physiology. Heart and circulatory physiology.

[26]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[27]  Carl T Wittwer,et al.  Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. , 2004, Clinical chemistry.

[28]  M. Laakso,et al.  Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes , 2004, Annals of medicine.

[29]  V. Regitz-Zagrosek,et al.  The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. , 2003, European heart journal.

[30]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[31]  K. Hayashi,et al.  A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. , 2003, Journal of the American College of Cardiology.

[32]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[33]  J. Seidman,et al.  Homozygous Mutation in Cardiac Troponin T: Implications for Hypertrophic Cardiomyopathy , 2000, Circulation.

[34]  J. Daubert,et al.  Homozygotes for a R869G mutation in the beta -myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.

[35]  J. Moolman-Smook,et al.  The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. , 1999, American journal of human genetics.

[36]  M. Komajda,et al.  Double heterozygosity for mutations in the β-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy , 1999, Journal of medical genetics.

[37]  A. Kisanuki,et al.  Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. , 1998, Circulation.

[38]  M. Komajda,et al.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. , 1997, Circulation research.

[39]  T. Kishimoto,et al.  A novel deletion mutation in the beta-myosin heavy chain gene found in Japanese patients with hypertrophic cardiomyopathy. , 1995, Journal of molecular and cellular cardiology.

[40]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[41]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[42]  M. Grompe,et al.  The rapid detection of unknown mutations in nucleic acids , 1993, Nature genetics.

[43]  F. T. ten Cate,et al.  Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. , 2009, JACC. Cardiovascular imaging.

[44]  H. Mabuchi,et al.  A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death. , 2006, Clinical science.

[45]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.

[46]  S. Solomon,et al.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. , 1994, The Journal of clinical investigation.